Mitral-valve prolapse.

TL;DR: In this paper, the authors provide comprehensive and timely evidence-based recommendations on the prevention of ischemic stroke among survivors of stroke or transient ischemi stroke, including the control of risk factors, interventional approaches for atherosclerotic disease, antithrombotic treatments for cardioembolism, and the use of antiplatelet agents for noncardioembolic stroke.

TL;DR: Evidence-based recommendations are included for the control of risk factors, interventional approaches for atherosclerotic disease, antithrombotic treatments for cardioembolism, and the use of antiplatelet agents for noncardioembolic stroke.

TL;DR: This guideline provides recommendations based on the optimal balance of thrombotic and hemorrhagic risk in valvular disease and recommends vitamin K antagonist therapy for rheumatic mitral disease and valve repair.

TL;DR: Most patients with echocardiographic evidence of mitral-valve prolapse have a benign course, but subsets at high risk for the development of progressive mitral regurgitation, sudden death, cerebral embolic events, or infective endocarditis can be identified by echOCardiography.

TL;DR: In a regionally selected patient population most closely resembling the true disease state, HCM did not significantly increase the risk of premature death or adversely affect overall life expectancy.

TL;DR: Although little hemodynamic alteration is present, these patients are presumably potential candidates for subacute bacterial endocarditis, and, in younger patients, prophylaxis against rheumatic activity is indicated.

TL;DR: Mitral valve prolapse and, in the elderly, degenerative lesions have displaced rheumatic and congenital heart diseases as the major conditions underlying endocarditis.

TL;DR: The present study examines the etiology of the valvular disease in 97 patients over the age of 30 years in whom MVR was carried out for severe, chronic, pure MR unassociated with MS or aortic valve dysfunction.